Le Bruyère 2000 - Bat 2
Zone le Millénaire, 650 rue Henri Becquerel
Tel: 33 4 67 20 77 30
27 articles with Sensorion
Sensorion announced the last patient's last visit in its Phase 2 clinical trial for SENS-111 investigated for the potential treatment of Acute Unilateral Vestibulopathy
Sensorion has contributed two presentations in the scientific poster session at the 2019 Annual Meeting of the American Academy of Otolaryngology, Head and Neck Surgery/Foundation held in New Orleans LA, the 15-18th of September, 2019.
Sensorion has contributed three presentations at the 56th Workshop on Inner Ear Biology (IEB 2019) held in Padua, the 7-10th of September, 2019.
Sensorion Announces Appointment of John Furey, Former COO of Spark Therapeutics, as Independent Board Member
Sensorion announces that John Furey will join the board of directors as an independent board member.
Sensorion a pioneering clinical-stage biopharmaceutical company which specialises in the development of novel therapies to restore, treat and prevent inner ear diseases such as hearing loss, tinnitus and vertigo held its combined general meeting on July 29, 2019.
Sensorion announces that it has received the Investigational New Drug clearance from the US Food and Drug Administration to proceed with SENS-401, based on preclinical data and clinical development plan.
Sensorion Announces an Oral Presentation at the 5th Congress of European ORL-Head & Neck Surgery in Brussels
Participation in the round table session named "Novel hearing therapeutics; what does it mean for the ENT surgeon?"
Sensorion Receives European Medicines Agency Agreement on the Pediatric Investigation Plan (PIP) for Arazasetron (SENS-401) in Two Indications
Sensorion announces that the European Medicines Agency has accepted its Pediatric Investigation Plan for both development in the treatment of severe hearing loss and for prevention of ototoxicity caused by cisplatin in the pediatric population.
Sensorion Announces That the “AUDINNOVE” Project of Which Sensorion Is a Partner Is a Laureate of the Fourth Solicitation Request for Funding From RHU as Part of the French “Avenir Investment Program”
The "AUDINNOVE" project led by AP-HP in partnership with Institut Pasteur, “la Fondation pour l’Audition” and Sensorion will receive a € 9.7m grant funding
6/13/2019Companies from across the globe share business and pipeline updates.
Sensorion Announces a €20m Convertible Bond Issue Subscribed by Two Renowned Investors Invus and Sofinnova Partners
Sensorion announces a convertible bond issue with a nominal value of 20 million euros subscribed by two new investors, Invus Public Equities LP as the anchor investor and Sofinnova Crossover I SLP as co-anchor investor.
Presentation of SENS-111 phase 2 study protocol in Acute Unilateral Vestibulopathy (AUV)
Sensorion a pioneering clinical-stage biopharmaceutical company which specialises in the development of novel therapies to restore, treat and prevent inner ear diseases such as hearing loss, tinnitus and vertigo held its combined general meeting on May 28, 2019.
Sensorion Announces the Signature of a Partnership Framework Agreement with Institut Pasteur on Gene Therapy Programs Targeting Hearing Loss
This agreement defines an exclusive option to obtain licences for joint programs including Otoferlin & Usher Type 1 and preference rights on the research pipeline in the field of genetic disorders of the inner ear in order to set up future collaborations
Sensorion a pioneering clinical-stage biopharmaceutical company which specializes in the development of novel therapies to restore, treat and prevent inner ear diseases such as hearing loss, tinnitus and vertigo, will present a keynote plenary lecture at the European Histamine Research Society in Kraków, Poland from May 15-18th, 2019.
Sensorion Announces the Positive Data Safety Monitoring Board (DSMB) Review and Continuation of the Phase 2 Clinical Trial for SENS-111 in Acute Unilateral Vestibulopathy (AUV)
Sensorion announced that the independent Data Safety Monitoring Board has undertaken a review of the safety data for the 76 first patients having completed the phase 2 clinical trial for SENS-111 in the treatment of acute unilateral vestibulopathy.
SENS-111 phase 2 AUV trial: major progress with 75% of patients enrolled in the clinical trial assessing the efficacy of SENS-111 on vertigo intensity
Sensorion strengthens its financial structure by issuing a €4.7 million nominal bond issue subscribed by new European investors and management
Sensorion announced a €4.7 million nominal bond issue, consisting of one (i) convertible bond issue1 for a nominal amount of €3,4 million subscribed by several new European investors as well as a bond issue2 for a nominal amount of €1.3 million subscribed by these same European investors for an amount of €1 million and the balance by the Company's management, Mr. Patrick Langlois, Chairman of the Board of Directors and Ms. Nawal Ouzren, Chief Executive Officer.
Sensorion and Cochlear Announce Collaboration to Study Combination Therapies for Cochlear Implant...
12/19/2017The collaboration will evaluate therapeutic approaches using SENS-401 in combination with cochlear implants, with preclinical studies initiating in 2018, and potential clinical trials to begin as soon as 2019.
Sensorion announces its results for the first half of the year ending June 30, 2017, as well as its recent developments.